Abstract:Marina Labor, 1 Brian K Kirui, 2 Fredrik Nyberg, 2 Lowie EGW Vanfleteren 3, 4 1 Cancer and Lung Health Care Unit, University Hospital in Linköping, Linköping, Sweden; 2 School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 3 COPD Center, Department of Respiratory Medicine and Allergology, Sahlgrenska University Hospital, Gothenburg, Sweden; 4 Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Correspondence: Marina Labor, Cancer and Lung Health Care Unit, University Hospital in Linköping, Linköping, Sweden, Tel +46739238935, Email Purpose: Population-based studies provide conflicting evidence about how inhaled corticosteroids (ICS) impact COVID-19 outcomes among COPD patients. We investigated whether regular ICS exposure affects risk, severity, or survival in SARS-CoV-2 infection, using a nationwide linked Swedish population register database. Patients and Methods: During January–December 2020, we studied two defined Swedish adult populations – Whole population [≥ 40 years] (N = 5243479), and COPD subpopulation [≥ 40 years] (N = 133372), in three study cohorts, respectively: 1. Overall cohort (index date 1 Jan 2020), 2. COVID-19 diagnosed sub-cohort (index date = diagnosis date), and 3. COVID-19 hospitalized sub-cohort (index date = admission date). Regular exposure was defined as ≥ 3 ICS prescriptions in the year before index. Hazard ratios (HRs) for outcomes (COVID-19 onset, hospitalization, ICU admission, or death) related to ICS exposure were estimated using Cox regression. Confounding was controlled by propensity score methods applying Average Treatment effect in the Treated (ATT) weighting. Results: Regular ICS use was associated with only very slightly increased onset of COVID-19, hospitalization, ICU admission, and death in the overall whole population cohort and in the overall COPD subpopulation cohort, except for ICU admission (marginally non-significant HRs, up to 1.13); and no clear increase in the diagnosed sub-cohorts. However, in the COVID-19 hospitalized COPD sub-cohort, ICS therapy showed reduced risks against progression to ICU admission and death, significant for death (HR 0.82 95% CI [0.67– 0.99]). Conclusion: For COPD patients, ICS therapy offers some protection against progression to ICU admission and death among COVID-19 hospitalized patients. Our findings alleviate concerns about increased risks of COVID-19 by ICS treatment and provide evidence supporting the continuation of ICS therapy for COPD patients. Keywords: COVID − 19, COPD, mortality Patients with chronic obstructive pulmonary disease (COPD) are of particular interest in relation to coronavirus disease 2019 (COVID-19) because COPD is a highly prevalent disease that is associated with impaired lung function. Overall, COPD patients seem not to have an increased risk of acquiring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 1 In contrast, it has been shown that COPD patients with COVID-19 have more than fivefold increased risk of a severe disease course requiring intensive care unit (ICU) support, and higher mortality in comparison to other patient groups, 2 which is at least partly explained by higher age and comorbidity prevalence. 3–6 Inhaled corticosteroids (ICS) are commonly used in patients with COPD to prevent exacerbations and/or control symptoms. Early in the COVID-19 pandemic, concerns were raised related to potential impaired antiviral response associated with ICS use, due to suppression of interferon-mediated innate and adaptive immunity. 7 Consequently, ICS users would have higher risk for severe illness if they acquired COVID-19. To date, published (mostly laboratory) studies and reviews rather suggest a potential preventive effect of pre-morbid and continued use of ICS against a hyperinflammatory response. 8–10 A recent study, in contrast, reported that pre-morbid ICS use in COPD was not protective and even increased risk of developing COVID-19. 11 A systematic review of more recent studies about pre-morbid and continued use of ICS found no evidence that ICS use was associated with worse outcomes, even though results and conclusions are likely confounded by different factors (ICS indication, sample size, lack of adjustment for comorbidities). 6 Current recommendations are that standard maintenance and exacerbation ICS therapy should not be discontinued, because maintenance of optimal pharmacologic treatment generally is the best way to prevent exacerbations and/or redu -Abstract Truncated-

Influenza Vaccination in Adults in the United States with COPD before and after the COVID-19 Pandemic (2017–2022): A Multi-Year Cross-Sectional Study

The Current Status of Vaccine Uptake and the Impact of COVID-19 on Intention to Vaccination in Patients with COPD in Beijing

[Status of Vaccination and Related Influencing Factors in Patients with Chronic Obstructive Pulmonary Disease: a Real-World Cross-Sectional Study].

Impact of the surge of COVID-19 Omicron outbreak on the intention of seasonal influenza vaccination in Hong Kong: A cross-sectional study

Combating the Co-Circulation of SARS-CoV-2 and Seasonal Influenza: Identifying Multi-Dimensional Factors Associated with the Uptake of Seasonal Influenza Vaccine among a Chinese National Sample

Influenza vaccination patterns among at-risk patients during the Covid-19 pandemic—a retrospective cross-sectional study based on claims data

Influenza Vaccination and the Risk of Ventricular Arrhythmias in Patients With Chronic Obstructive Pulmonary Disease: A Population-Based Longitudinal Study

Influenza and Pneumococcal Vaccination Coverage and Associated Factors in Patients Hospitalized with Acute Exacerbations of COPD in China: Findings from Real-World Data.

Influenza and pneumococcal vaccination coverage and associated factors in patients hospitalized with acute exacerbations of COPD in China: Findings from the real-world data

Influenza and pneumococcal vaccination in patients with COPD from 3 French cohorts: Insufficient coverage and associated factors

The Effectiveness of Influenza Vaccination on Chronic Obstructive Pulmonary Disease with Different Severities of Airflow Obstruction

The status and influencing factors of COVID-19 vaccination in patients with COPD

Impact of COVID-19 Vaccine Rollout on Mental Health, Social Determinants of Health, and Attitudes Among Individuals With COPD

Long COVID among US adults from a population-based study: Association with vaccination, cigarette smoking, and the modifying effect of chronic obstructive pulmonary disease (COPD)

Changes in the Pneumococcal Vaccination Uptake and Its Determinants before, during, and after the COVID-19 Pandemic among Community-Living Older Adults in Hong Kong, China: Repeated Random Telephone Surveys

Impact of COVID-19 pandemic on influenza vaccination rate among health care workers

Influenza vaccine uptake among youth with sickle cell disease who are seen in clinic before and after the COVID-19 pandemic

Prevalence and disparities in influenza vaccination among patients with COPD: A French nationwide population study

The Association between Influenza and Pneumococcal Vaccinations and SARS-Cov-2 Infection: Data from the EPICOVID19 Web-Based Survey

Regular Inhaled Corticosteroids Use May Protect Against Severe COVID-19 Outcome in COPD

Effectiveness of influenza and pneumococcal vaccines on chronic obstructive pulmonary disease exacerbations